

# Docking Prediction for Six Phenolic Compounds Inhibiting TNF- $\alpha$ and NF- $\kappa$ B Pathway

孫瑞強、李世傑、李桂仁

E-mail: 387168@mail.dyu.edu.tw

## ABSTRACT

In this article, we select 6 frequently used polyphenols with strong efficacy from anti-inflammatory herbal medicines: curcumin, EGCG (epigallocatechin-3-gal-late), sinapyl alcohol, syringin, triptolide and luteolin to perform docking study. First part addresses on extracellular links to TNF- $\alpha$ . We dock TNF- $\alpha$  with curcumin, EGCG, sinapyl alcohol, syringin, triptolide and luteolin by Autodock 4, respectively. We discover that triptolide and curcumin have stronger effect and better stability on inhibiting TNF- $\alpha$  in these six polyphenols. There are three combinatives of compounds on inhibiting TNF- $\alpha$ : (1). Curcumin, EGCG, sinapyl alcohol and luteolin. (2). Curcumin, sinapyl alcohol, syringin and luteolin. (3). EGCG, syringin, triptolide and luteolin. In the second part, we discuss luteolin inhibits NF- $\kappa$ B pathway in intracellular. We use luteolin as ligand, NF- $\kappa$ B pathway in intracellular as macromolecular to perform docking prediction with Autodock 4. We discovered that luteolin can strongly inhibit TRAF2 and TNFR1; dock with RIP1 to block the signal passing of RIP1; strongly dock with C-terminal of IKK to inhibit IKK $\alpha$ , IKK $\beta$  and IKK $\gamma$  from forming trimer. In other words, luteolin can be an inhibitor for TNF- $\alpha$  on extracellular and NF- $\kappa$ B pathway in intracellular.

Keywords: Curcumin, EGCG, syringin, sinapyl alcohol, Triptolide, Luteolin, NF- $\kappa$ B pathway

## Table of Contents

|  |     |   |     |
|--|-----|---|-----|
| 目錄 封面內頁 簽名頁 中文摘要.....  | iii | 英文摘要.....   | iii |
| .....v 誌謝.....   | vi  | 目錄.....   | ix  |
| .....vii 圖目錄.....  | ix  | 表目錄.....  | ix  |
| .....xi 第一章 緒言.....  | 1   | 第一節 研究背景與動機.....  | 1   |
| .....1 第二節 研究問題與目的.....  | 2   | 第二章 文獻回顧.....   | 6   |
| 第一節 TNF- $\alpha$ 和NF- $\kappa$ B對於人體的保護及引起的疾病.....  | 6   | 第二節 六種多酚：薑黃素、兒茶素、芥子醇、丁香?、雷公藤甲素和木犀草素抑制TNF- $\alpha$ 的活性的相關研究.....      | 13  |
| 第三節 木犀草素抑制核因子- $\kappa$ B的相關研究.....  | 17  | 第四節 SWISS-MODEL Workspace的相關研究.....                                   | 18  |
| 第五節 Autodock 4 (包含ADT)的相關研究.....   | 20  | 第六節 LIGPLOT的相關研究.....   | 21  |
| 第七節 SwissPdb Viewer的相關研究.....  | 22  | 第八節 PROCHECK的相關研究.....  | 22  |
| 第九節 VERIFY3D的相關研究.....   | 23  | 第十節 ERRAT的相關研究.....   | 24  |
| 第十一節 ChemSpider.....   | 24  | 第三章 材料與方法.....  | 25  |
| 第一節 六種多酚對於腫瘤壞死因子- $\alpha$ 的對接預測.....  | 25  | 第二節 木犀草素抑制核因子- $\kappa$ B途徑的對接預測.....                                 | 34  |
| 第四章 結果與討論.....   | 44  | 第一節 六種多酚對於腫瘤壞死因子- $\alpha$ 的對接預測的結果.....                              | 44  |
| 第二節 木犀草素抑制核因子- $\kappa$ B的對接預測的結果.....   | 60  | 第五章 結論.....   | 72  |
| 參考文獻.....  | 76  | 附錄.....   | 89  |
| 圖目錄 圖目錄 圖3.1 儲存到AutoDock中的1A8MB的DeepView project的pdb檔.....   | 28  | 圖3.2 6個多酚的化學結構：(a).薑黃素 (b).兒茶素 (c).芥子醇 (d).丁香? (e).雷公藤甲素 (f).木犀草..... | 33  |
| 圖3.3a 儲存到AutoDock中的 TNFR(41到201) 1extA的 Deep View project的pdb檔.....                                      | 38  | 圖3.3b 儲存到AutoDock中的TNFR(356到442)1ichA的DeepView project的pdb檔.....      | 39  |
| 圖3.4 儲存到AutoDock中的 TRADD(1f2hA)的Deep View project的pdb檔.....  | 40  | 圖3.5 儲存到AutoDock中的 TRAF2(1ca9B)的DeepView project的pdb檔.....            | 41  |
| 圖3.6 儲存到AutoDock中的 RIP1 ( 1qcfA ) 的DeepView project的pdb檔.....  | 42  | 圖3.7 儲存到AutoDock中的IKK ( 1cm8B ) 的DeepView project的pdb檔.....           | 43  |
| 圖4.1 這六個多酚和TNF- $\alpha$ 表面的對接結果.....  | 52  | 圖4.2 TNF- $\alpha$ 中相同口袋的對接配體群.....                                   | 53  |
| 圖4.3 配體：薑黃素、兒茶素、芥子醇、丁香?、雷公藤甲素和木犀草素的凡得瓦爾力和氫鍵作用力.....  | 54  | 圖4.4 對接結果中的 $\pi$ - $\pi$ 型態原子之間的作用力和 $\pi$ -陽離子的作用力.....             | 57  |
| 圖4.5 對接結果中的 $\pi$ - $\pi$ 型態原子之間的作用力和 $\pi$ -陽離子的作用力.....  | 68  | 表目錄 表3.1 TNF- $\alpha$ ( 1A8MB ) 同源模型的模板和品質.....                      | 27  |
| 表3.2 在ChemSpider( <a href="http://www.chemspider.com/">http://www.chemspider.com/</a> )的小分子的最新發表的資料..... | 31  | 表3.3 模板和同源模型的品質.....  | 37  |
| 表4.1 以AUTODOCK 4.0所計算出的能量能量(以kcal/ mol表示).....   |     |   |     |

|   |  |
|---|--|
| .....48 表4.2 氫鍵作用力以及每一個氫鍵的能量.....                           | 58 表4.3 凡得瓦爾力.....   |
| ... 59 表4.4 AUTODOCK 4.0計算出的能量(kcal/mol).....               | 67 表4.5 氫鍵相互作用和每一個鍵的能量.....  |
| ...69 表4.6 凡得瓦力作用力.....                                     | 70 表4.7 疏水性作用力.....  |
| 71 附錄 附錄1 名詞對照表.....  | 89 附錄2 發表論文列表.....   |
| ..... 94 附錄3發表論文.....                                       | 95 附錄4 SCI發表論文.....  |
| .... 96 附錄5 autodock(介紹).....                               | 97 附錄6 ChemSpider(介紹).....   |
| ....100 表目錄 表3.1 TNF – ( 1A8MB ) 同源模型的模板和品質.....            | 27 表3.2 在ChemSpider(<br>http://www.chemspider.com/)的小分子的<br>最新發表的資料..... |
| ..... 37 表4.1 以AUTODOCK 4.0所計算出的<br>能量能量(以kcal/ mol表示)..... | 31 表3.3 模板和同源模型的品質...  |
| ..... 48 表4.2 氫鍵作用力以及每一個氫鍵的能量.....                          | 58 表4.3 凡得瓦爾力.....   |
| ..... 59 表4.4 AUTODOCK 4.0計算出的<br>能量(kcal/mol).....         | 67 表4.5 氫鍵相互作用和每一個鍵的能量.....  |
| ... 69 表4.6 凡得瓦力作用力.....                                    | 70 表4.7 疏水性作用力.....  |
| 71 附錄 附錄1 名詞對照表.....  | 89 附錄2 發表論文列表.....   |
| ..... 94 附錄3發表論文.....                                       | 95 附錄4 SCI發表論文.....  |
| .... 96 附錄5 autodock(介紹).....                               | 97 附錄6 ChemSpider(介紹).....   |
| ..... 100   |  |

## REFERENCES

1. Abdelhamid, L., Judith, S. and Muhammad, Z. 2005. Triptolide suppresses proinflammatory cytokine-induced matrix metalloproteinase and aggrecanase-1 gene expression in chondrocytes. *Biochemical and Biophysical Research Communications* 327,320-327.
2. Aggarwal, B. B. and Shishodia, S. 2004. Suppression of the nuclear factor-kB activation pathway by spice-derived phytochemicals: reasoning for seasoning. *Ann NY Acad Sci* 1030,434 – 441.
3. Agullo, G., Gamet-Payraastre, L., Manenti, S., Viala, C., Remesy, C., Chap, H. and Payraastre, B. 1997. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition, *Biochem. Pharmacol* 53, 1649 – 1657.
4. Ahima, R. S. and J.S. Flier. 2000. " Leptin " , *Annu. Rev. Physiol* 62, 413.
5. Arbibe, L., D. Vial, I. R. Chupin, N. Havet, M., Huerre, B. B., Vargaftig, and L. Tourqui.1997. Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs. *J. Immunol* 159, 391.
6. Arenzana-Seisdedos, F., Thompson, J., Rodriguez, MS., Bachelierie, F., Thomas, D. and Hay, RT. 1995 .Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. *Mol Cell Biol*.15:2689 – 2696.
7. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T., Miyaoaka, K., Kuriyama, H., Nishida, M., Yamashita, S., Okubo, K., Matsubara, K., Muraguchi, M., Ohmoto, Y., Funahashi, T. and Matsuzawa, Y. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun* 257,79 – 83.
8. Arner, P. 2002. Insulin resistance in type 2 diabetes: role of fatty acids. *Diabetes Metab. Res. Rev* 18 (Suppl. 2), 5 – 9.
9. Arnold, K., Bordoli, L., Kopp, J. and Schwede, T. 2006. The SWISS-MODEL Work space: A web-based environment for protein structure homology modeling. *Bioinformatics* .22, 195-201.
10. Baeuerle, P. A. and Henkel, T. 1994. Function and activation of NF-kB in the immune system. *Annu. Rev. Immunol* 12, 141 – 179.
11. Baldwin, A. S. 1996. The NF- B and I B proteins: new discoveries and insights. *Annu. Rev. Immunol* 14, 649 – 681.
12. Barry, M. A. and Eastman, A. 1993. Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. *Arch. Biochem. Biophys.* 300, 440 – 450.
13. Beutler, B. and Cerami, A. 1986. Cachectin and tumour necrosis factor as two sides of the same biological coin. *Nature* 320, 584 – 588.
14. Bowie, J. U., Luthy, R. and Eisenberg, D. 1991.A method to identify protein sequences that fold into a known three-dimensional structure. *Science* 253,164-170.
15. Bowie, J. U., Eisenberg, D. and Luthy, R. 1992. Assessment of protein models with three-dimensional profiles. *Nature* .365,83-85.
16. Bradley, JR. 2008. TNF-mediated inflammatory disease. *J Pathol* 214: 149 – 160.
17. Brown, NR., Noble, ME., Endicott, J. A. and Johnson, L. N.1999. The structure basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.*Nat Cell Biol*.1(7):438-43.
18. C. Hubac., J. Ferran., A. Tremolieres. and A. Kondorosi. 1994. Luteolin uptake by *Rhizobium meliloti*: evidence for several steps including an active extrusion process. *Microbiology*. 140,2769-2774.
19. Cabannes, E., Khan,G., Aillet, F., Jarrett, RF. and Hay, RT. 1999. Mutations in the Ikb gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. *Oncogene* 18 (20): 3063 – 70.
20. Chan, FK., Siegel, RM. and Lenardo, MJ. 2000. Signaling by the TNF receptor superfamily and T cell homeostasis. *Immunity* 13, 419-422.
21. Chen, ZJ .2005. Ubiquitin signalling in the NF-kappaB pathway. *Nat Cell Biol* 7: 758 – 765.
22. Chen, C.Y., Peng, W. H., Tsai, K. D. and Hsu, S. L. 2007. Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. *Life. Sci.* 30, 1602 – 1614.
23. Cho, J. Y., Nam, K. H., Kim, A. R., Park, J., Yoo, E. S., Baik, K. U., Yu, Y. H. and Park, M. H. 2001. In-vitro and in-vivo immunomodulatory effects of syringin. *J. Pharm Pharmacol* .53,1287-1294.
24. Choi, YJ., Kim, TG. and Kim, YH. 2003 . Immunosuppressant PG490 (triptolide) induces apoptosis through the activation of caspase-3 and down-regulation of XIAP in U937 cells. *Biochem Pharmacol* .66:273-280.
25. Choi, J., K. M. Shin, H. J. Park, H. J. Jung, H. J. Kim, Y. S. Lee, J. H. Rew, and K. T. Lee. 2004. Anti-inflammatory and antinociceptive effects of sinapyl alcohol and its glucoside syringin. *Planta Med.* 70,1027.
26. Collins, T. and Cybulsky, M. I. 2001. NF- B: pivotal mediator or innocent bystander in atherogenesis? *J. Clin. Invest.* 107,255 – 264.
- 27.

Colovos, C. and Yeates, T. O. 1993. Verification of protein structures: patterns of nonbonded atomic interactions. *Protein Sci.* 2, 1511-1519. 28.

Cunningham, B. D., Threadgill, M. D., Groundwater, P. W., Dale, I. L. and Hickman, J. A. 1992. Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases. *Anticancer Drug Des.* 7, 365 – 384. 29.

De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, DU., Jin, R., Jones, J., Cong, R. and Franzoso, G. 2001. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. *Nature*, 414, 308 – 313. 30.

Devin, A., Cook, A., Lin, Y., Rodriguez, Y. and Kelliher, M. 2000. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. *Immunity* 12:419-429. 31.

Devin, A., Lin, Y., Yamaoka, S., Li, Z. and Karin, M. 2001. The alpha and beta subunits of IkappaB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF. *Mol Cell Biol.* 21:3986-3994. 32.

Dong, C., Davis, R.J. and Flavell, R.A. 2002. MAP kinases in the immune response. *Annu Rev Immunol* 20:55 – 72. 33.

Favelyukis, S., Till, J.H., Hubbard, S.R. and Miller, W.T. 2001. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. *Nat Struct Biol.* 8(12):1058-63. 34.

Feingold, K. R., Marshall, M., Gulli, R., Moser, A. H. and Grunfeld, C. 1994. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. *Arteriosclerosis and Thrombosis* 14, 1866 – 1872. 35.

Feingold, K. R., Hardardottir, I. and Grunfeld, C. 1998. Beneficial effects of cytokine induced hyperlipidemia. *Z. Ernahrungswiss*; 37 Suppl. 1, 66 – 74. 36.

Ferrero-Miliani, L., Nielsen, O. H., Andersen, P. S. and Girardin, S. E. 2007. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1 beta generation. *Clin. Exp. Immunol.* 147,227 – 235. 37.

Ferriola, P. C., Cody, V. and Middleton, E. Jr. 1989. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. *Biochem Pharmacol* 38,1617 – 1624. 38.

Festjens, N., T. Vanden, Berghe, S. Cornelis, and P. Vandenabeele. 2007. RIP1, a kinase on the crossroads of a cell's decision to live or die. *Cell Death Differ.* 14:400 – 410. 39.

Fotsis, T., Pepper, M. S., Aktas, E., Breit, S., Rasku, S., Adlercreutz, H., Wahala, K., Montesano, R. and Schweigerer, L. 1997. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. *Cancer Res.* 57, 2916 – 2921. 40.

Galluzzi, L., O. Kepp, and G. Kroemer. 2009b. RIP kinases initiate programmed necrosis. *J. Mol. Cell. Biol.* 1:8 – 10. 41.

Ghosh, S., May, M. J. and Kopp, E. B. 1998. NF- $\kappa$ B and Rel proteins: evolutionarily conserved mediators of immune responses. *Annu. Rev. Immunol.* 16,225 – 260. 42.

Gilmore, T. D. 2006. Introduction to NF-kappaB: players, pathways, perspectives. *Oncogene* 25, 6680 – 6684. 43.

Graziani, Y., Erikson, E. and Erikson, R. L. 1983. The effect of quercetin on the phosphorylation of the Rous sarcoma virus transforming gene product in vitro and in vivo. *Eur J Biochem* 135,583 – 589. 44.

Grunfeld, C. and Feingold, K. R. 1991. Tumour necrosis factor, cytokines and the hyperlipidemia of infection. *Trends Endocrinol Metab.* 2, 213 – 219. 45.

Guex, N. and Peitsch, M. C. 1997. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. *Electrophoresis* .18, 2714-2723. 46.

Harborne, J. B. and Williams, C. A. 2000. Advances in flavonoid research since 1992. *Phytochemistry* .55,481 – 504. 47.

Hayden, M. S. and Ghosh, S. 2008. Shared principles in NF-kappaB signaling. *Cell* 132,344 – 362. 48.

Hikim, A. P. S., Lue, Y. H., Wang, C., Reutrakul, V., Sangsuwan, R., Swerdloff, R. S., 2000. Post-testicular antifertility action of triptolide in the male rat: evidence for severe impairment of caudal epididymal sperm ultrastructure. *J. Androl.* 21 (3), 431 – 437. 49.

Hsu, H., Xiong, J. and Goeddel, D.V. 1995. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. *Cell* .81,495-504. 50.

Huang, Y. T., Hwang, J. J., Lee, P. P., Ke, F. C., Huang, J. H., Huang, C. J., Kandaswami, C., Middleton, E. Jr. and Lee, M. T. 1999. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. *Br. J. Pharmacol.* 128, 999 – 1010. 51.

Huey, R., Morris, G. M., Olson, A. J. and Goodsell, D. S. 2007. A Semiempirical Free Energy Force Field with Charge-Based Desolvation. *J Comput Chem* 28, 1145-1152. 52.

Hymowitz, S.G., Christinger, H.W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R.F., Ashkenazi, A. and de Vos, A.M. 1999. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. *Mol Cell* 4(4):563-71. 53.

Izumi, K.M., Cahir-McFarland, E.D., Ting, A.T., Riley, E.A. and Seed, B. 1999. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. *Mol Cell Biol* 19, 5759 – 5767. 54.

Jacobs, M.D. and Harrison, S.C. 1998. Structure of an IkappaBalpha/ NF-kappaB complex. *Cell* 95 (6), 749 – 58. 55.

Kagan, B. L., Baldwin, R. L., Munoz, D. and Wisnieski, B. J. 1992. Formation of Ion-Permeable Channels by Tumor Necrosis Factor-Alpha. *Science* 255, 1427-1430. 56.

Kang, O. H., Choi, J. G., Lee, J. H. and Kwon, D. Y. 2010. Luteolin Isolated from the Flowers of *Lonicera japonica* Suppresses Inflammatory Mediator Release by Blocking NF- $\kappa$ B and MAPKs Activation Pathways in HMC-1 Cells. *Molecules* 15, 385-398. 57.

Karin, M. 2006. Nuclear factor- $\kappa$ B in cancer development and progression. *Nature* 441, 431-436. 58.

Kelliher, M.A., S. Grimm, Y. Ishida, F. Kuo, B., Z. Stanger. and P. Leder. 1998. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. *Immunity*. 8,297 – 303. 59.

Kempuraj, D., Tagen, M., Iliopoulou, B. P., Clemons, A., Vasiadi, M., Boucher, W., House, M., Wolfberg, A. and Theoharides, T.C. 2008. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. *Br. J. Pharmacol.* 155, 1076-1084. 60.

Kiefer, F., Arnold, K., Kunzli, M., Bordoli, L. and Schwede, T. 2009. The SWISS-MODEL Repository and associated resources. *Nucleic Acids Res.* 37,D387-392. 61.

Kim, J. S. and Jobin, C. 2005. The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. *Immunology*. 115, 375-387. 62.

Kim, K.Y., Kim, J.K., Jeon, J.H., Yoon, S.R., Choi, I. and Yang, Y. 2005. c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF- $\alpha$  in 3T3-L1 adipocytes. *Biochem Biophys Res Commun.* 327, 460 – 467. 63.

Kimata, M., Shichijo, M., Miura, T., Serizawa, I., Inagaki, N. and Nagai, H. 2005. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. *Clin. Exp. Allergy* .30,501-508. 64.

Kelliher, M.A., S. Grimm, Y. Ishida, F. Kuo, B., Z. Stanger, and P. Leder. 1998. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. *Immunology*. 8,297 – 303. 65.

Kempuraj, D., Madhappan, B.,

Christodoulou, S., Boucher, W., Cao, J., Papado-poulou, N., Cetrulo, C. L. and Theoharides, T. C. 2005. Flavonols inhibit pro-inflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. *Br. J. Pharmacol.* 145,934-944.

66. Kiviharju, T.M., Lecane, P.S., Sellers, R.G. and Peehl, D.M. 2002. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. *Clin Cancer Res.* 8,2666 – 2674.

67. Kupchan, S. M., Court, W. A., Dailey, R.G. Jr., Gilmore, C.J., Bryan, R. F. 1972. Triptolide and triptolide novel antileukemic diterpenoid triepoxides from *Tripterygium wilfordii*. *J. Am. Chem. Soc.* 94, 7194 – 7195.

68. Lam, J., Nelson, C. A., Ross, F.P., Teitelbaum, S.L., Fremont, D.H. 2001. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. *J Clin Invest*, 108(7):971-9.

69. Laskowski, R. A., MacArthur, M.W., Moss, D. S., Smith, D. K. and Thornton, J. M. 1993. PROCHECK: a program to check the stereochemical quality of protein structures. *J. Appl. Cryst.* 26, 283-291.

70. Lee, K.Y., Chang, W., Qiu, D., Kao, P.N. and Rosen, G.D. 1999. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. *J Biol Chem.* 274,13451 – 13455.

71. Lee, K.Y., Park, J.S., Jee, Y.K. and Rosen, G.D. 2002. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. *Exp Mol Med.* 34,462-468.

72. Leuenroth, S.J. and Crews, C.M. 2005. Studies on calcium dependence reveal multiple modes of action for triptolide. *Chem Biol.* 12,1259 – 1268.

73. Li, Q., Verma, I.M. 2002. NF-kappaB regulation in the immune system. *Nat Rev Immunol.* 2, 975.

74. Liacini, A., Sylvester, J. and Zafarullah, M. 2005. Triptolide suppresses proinflammatory cytokine-induced matrix metalloproteinase and aggrecanase-1 gene expression in chondrocytes. *Biochem Biophys Res Commun.* 327, 320 – 327.

75. Liu, Q., Chen, T. and Chen, H. 2004. Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activation. *Biochem Biophys Res Commun.* 319,980-986.

76. Liu, K.Y., Wu, Y.C., Liu, I.M. and Cheng, J.T. 2008. Release of acetylcholine by syringin, an active principle of *Eleutherococcus senticosus*, to raise insulin secretion in Wistar rats. *Neurosci Lett.* 434(2),195-9.

77. Luftig, M., Prinarakis, E., Yasui, T., Tschritzis, T., Cahir-McFarland, E. 2003. Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. *Proc Natl Acad Sci U S A.* 100,15595 – 15600.

78. Madhusudan, Akamine, P., Xuong, N.H., Taylor, S. S. 2002. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. *Nat Struct Biol.* 9(4):273-7.

79. Manach, C. and Donovan, J. L. 2004. Pharmacokinetics and metabolism of dietary flavonoids in humans. *Free Radic. Res.* 38,771-785.

80. Mattson, M. P. and Camandola, S. 2001. NF- $\kappa$ B in neuronal plasticity and neurodegenerative disorders. *J. Clin. Invest.* 107, 247 – 254.

81. McWhirter, S.M., Pullen, S.S., Holton, J.M., Crute, J. J., Kehry, M.R., Alber, T. 1999. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. *Proc Natl Acad Sci USA.* 96(15):8408-13.

82. Memon, R. A., Grunfeld, C., Moser, A. H. and Feingold, K. R. 1993. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. *Endocrinology.* 132, 2246 – 2253.

83. Morris, A. L., MacArthur, M. W., Hutchinson, E. G. and Thornton, J. M. 1992. Stereochemical quality of protein structure coordinates. *Proteins.* 12, 345-364.

84. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K. and Olson, A. J. 1998. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. *J. Comput. Chem.* 19,1639-1662.

85. Muppidi, J.R., Tschopp, J. and Siegel, R.M. 2004. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. *Immunity.* 21, 461 – 465.

86. Nikaido, H. 1993. Transport across the bacterial outer membrane. *J Bioenerg Biomembr.* 25, 581-589.

87. Pando, M.P., Verma, I.M. 2000. Signal dependent and independent degradation of free and NF-kappa B-bound IkappaBalpha. *J Biol Chem.* 275,21278 – 86.

88. Park, H. H., Lee, S., Son, H.Y., Park, S. B., Kim, M. S., Choi, E. J., Singh, T. S., Ha, J. H., Lee, M. G., Kim, J. E., Hyun, M. C., Kwon, T. K., Kim, Y. H. and Kim, S. H. 2008. Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. *Arch. Pharm. Res.* 31,1303-1311.

89. Park, Y. C., Burkitt, V., Villa, A. R., Tong, L. and Wu, H. 1999. Structural basis for self-association and receptor recognition of human TRAF2. *Nature.* 398(6727):533-8.

90. Peitsch, M. C. 1995. Protein modeling by E-mail. *Nat. Biotechnol.* 13, 658-660.

91. Peraldi, P., Hotamisligil, G. S., Buurman, W. A., White, M. F. and Spiegelman, B. M. 1996. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55TNF receptor and activation of sphingomyelinase. *J. Biol. Chem.* 271, 13018 – 13022.

92. Pruzanski, W., Vadas, P., Browning, J. 1993. Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. *J. Lipid Mediat.* 8, 161 – 167.

93. Riaz, A. M., Walter, M. H., Arthur, H. M., Taisuke, S., Yoshikazu, U., John, F., Judy, K. S., Carl, G. and Kenneth, R. F. 1998. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin. *Arterioscler. Thromb. Vasc. Biol.* 18, 1257 – 1265.

94. Rink, L. and H. Kirchner. 1996. Recent Progress in the Tumor Necrosis Factor -Alpha Field. *Int. Arch. Allergy Immunol.* 111,199.

95. Ross, R. 1999. Atherosclerosis – an inflammatory disease. *N. Engl. J. Med.* 340, 115.

96. Saghizadeh, M., Ong, J.M., Garvey, W.T., Henry, R. R. and Kern, P.A. 1996. The expression of TNF alpha by human muscle. Relationship to insulin resistance. *J Clin Invest.* 15;97(4):1111-6.

97. Schomer-Miller, B., Higashimoto, T., Lee, Y. K. and Zandi, E. 2006. Regulation of IkappaB kinase (IKK) complex by IKKgamma-dependent phosphorylation of the T-loop and C terminus of IKKbeta. *J Biol Chem.* 281, 15268-15276.

98. Schwede, T., Kopp, J., Guex, N. and Peitsch, M. C. 2003. SWISS-MODEL: an automated protein homology-modeling server. *Nucleic Acids Re.* 31,3381 – 3385.

99. Shamon, L.A., Pezzuto, J.M., Graves, J.M., Mehta, R.R., Wangcharoentrakul, S., Sangsuwan, R., Chaichana, S., Tuchinda, P., Cleason, P. and Reutrakul, V. 1997. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from *Tripterygium wilfordii*. *Cancer Lett.* 112,113 – 117.

100. Shi, C.S. and Kehrl, J.H. 2003. Tumor necrosis factor (TNF)-induced germinal center kinase related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13 – Uev1A/TNF receptor-associated factor 2 (TRAF2). *J Biol Chem.* 278, 15429 – 15434.

101. Shimada, K., Miyazaki, T. and Daida, H. 2004. Adiponectin and atherosclerotic disease. *Clin Chim Acta.* 344,1 – 12.

102. Sica, A., Wang, J. M., Colotta, F., Dejana, E., Mantovani, A., Oppenheim, J. J., Larsen, C. G., Zachariae, C. O. and Matsushima,

K. 1999. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. *The Journal of Immunology*. 144, 3034 – 3038.

103. Skoog, T., Dichl, W., Boquist, S., Skoglund-Andersson, C., Karpe, F., Tang, R., Bond, MG., de Faire, U., Nilsson, J., Eriksson, P. and Hamsten, A. 2002. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. *Eur Heart J*. 23,376-383.

104. Stefan, N., Bunt, J., Slabe, A., Funahashi, T., Matsuzawa, Y. and Tataranni, P. 2002. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. *J. Clin Endocrinol Metab*. 87,4652 – 4656.

105. Sun, SC., Ganchi, PA., Ballard, DW., Greene, WC. 1993. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. *Science*. 259,1912 – 5.

106. Tak, P. P. and Firestein, G. S. 2001. NF- B: a key role in inflammatory diseases. *J. Clin. Invest*. 107,7 – 11.

107. Tang, G., Minemoto, Y., Dibling, B., Purcell, NH., Li, Z., Karin, M. and Lin, A. 2001. Inhibition of JNK activation through NF-kappaB target genes. *Nature*. 414, 313 – 317.

108. Tao, X., Davis, L. S. and Lipsky, P. E. 1991. Effect of an extract of the Chinese herbal remedy *Tripterygium wilfordii* Hook F on human immune responsiveness. *Arthritis Rheum*. 34, 1274 – 1281.

109. Tao, X., Cush, JJ., Garret, M. and Lipsky, PE. 2001. A phase I study of ethyl acetate extract of the chinese antirheumatic herb *Tripterygium wilfordii* hook F in rheumatoid arthritis. *J Rheumatol*. 28,2160 – 7.

110. Tao, X., Younger, J., Fan, F. Z., Wang, B. and Lipsky, P. E. 2002. Benefit of an extract of *Tripterygium wilfordii* Hook F in patients with rheumatoid arthritis. *Arthritis Rheum*. 46,1735 – 1743.

111. Theoharides, T. C., Dimitriadou, V., Letourneau, R. J., Rozniecki, J. J., Vliagoftis, H. and Boucher, W. S. 1993. Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain demyelination: changes resembling early stages of demyelination. *Neuroscience*. 57, 861 – 871.

112. Tracey, K. J. and Cerami, A. 1990. Metabolic responses to cachectin/TNF. A brief review. *New York Academy of Sciences*. 587,325-331.

113. Tracey, KJ. and Cerami, A. 1994. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. *Annu Rev Med*. 45,491-503.

114. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R. and Verma, I. M. 1996. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. *Science*. 274, 787-789.

115. Verma, IM., Stevenson, JK., Schwarz, EM., Van Antwerp, D., Miyamoto, S. 1995. "Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation". *Genes Dev*. 9 (22), 2723 – 35.

116. Vivarelli, M. S., D. McDonald, M. Miller, N. Cusson, M. Kelliher. and R. S. Geha. 2004. RIP links TLR4 to Akt and is essential for cell survival in response to LPS stimulation. *J. Exp. Med*. 200:399 – 404.

117. Wallace, A. C., Laskowski, R. A. and Thornton, J. M. 1995. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. *Protein Eng*. 8, 127-134.

118. Wei, YS. and Adachi, I. 1991. Inhibitory effect of triptolide on colony formation of breast and stomach cancer cell lines. *Chung Kuo Yao Li Hsueh Pao*. 12:406 – 410.

119. Wu, CJ., Conze, DB., Li, T., Srinivasula, SM., Ashwell, JD. 2006. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation. *Nat Cell Biol*. 8:398-406.

120. Xagorari, A., Papapetropoulos, A., Mauromatis, A., Economou, M., Fotsis, T. and Roussos, C. 2001. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. *J. Pharmacol. Exp. Ther*. 296, 181 – 187.

121. Yang, J., Cron, P., Good, VM., Thompson, V., Hemmings, BA. and Barford, D. 2002. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. *Nat Struct Biol*. 9(12):940-4.

122. Ye, H., Park, YC., Kreishman, M., Kieff, E. and Wu, H. 1999. The structural basis for the recognition of diverse receptor sequences by TRAF2. *Mol Cell*. 4(3):321-30.

123. Zhang, L. X., Pan, D. J., Zhang, W. J., Wu, H. Y. and Lou, W. P., 1986. Inhibitory effect of tripterygium on lymphocyte proliferation in mice. *Acta Pharm. Sin* 7, 85 – 88.